Reference:
1. Pichler WJ. Immune pathomechanism and classification of drug
hypersensitivity. Allergy. 2019;74:1457-1471.
2. Mayorga C, Fernandez TD, Montanez MI, Moreno E, Torres MJ. Recent
development and highlights in drug hypersensitivity. Allergy
2019;74:2368-2381.
3. Torres MJ, Adkinson NF, Caubet JC, et al; for the AAAAI/WAO 2018
Symposium Penicillin and Cephalosporin Allergy Testing Working Group.
Controversies in Drug Allergy: Beta-Lactam Hypersensitivity Testing. J
Allergy Clin Immunol Pract 2019;7:40-5.
4. Brockow K, Ardern-Jones MR, Mockenhaupt M, et al. EAACI position
paper on how to classify cutaneous manifestations of drug
hypersensitivity. Allergy 2019;74(1):14-27.
5. Calamelli E, Caffarelli C, Franceschini F, et al. A practical
management of children with antibiotic allergy. Acta Biomed 2019;90
(Supll 3):11-19.
6. Gomes E, Brockow K, Kuyucu S, et al, on behalf of the ENDA/EAACI Drug
Allergy Interst Group. Drug hypersensitivity in children: report from
the pediatric task force of the EAACI Drug Allergy Interest Group.
Allergy 2016; 71(2):149-61.
7. Caubet JC, Kaiser L, Lemaitre B, Fellay B, Gervaix A, Eigenmann PA.
The role of penicillin in bening skin rashes in childhood: a prospective
study based on drug rechallenge. J Allergy Clin Immunol
2011;127(1):218-222.
8. Atanaskovic-Markovic M, Gaeta F, Medjo B, et al. Non-immediate
hypersensitivity reactions to beta-lactam antibiotics in children-our
10-year experience in allergy work-up. Pediatr Allergy immunol
2016;27(5):533-538.
9. Norton AE, Konvinse K, Phillips EJ, Broyles AD. Antibiotic allergy in
pediatrics. Pediatrics 2018;141(5):e20172497.
10. Eigenmann PA, Akdis C, Bousquet J, et al. Highlights and recent
development in food and drug allergy, and anaphylaxis in EAACI Journals
(2017). Pediatr Allergy Immunol 2018;29:801-807.
11. Demoly P, Adkinson NF, Brockow K et al. International Consensus on
drug allergy. Allergy 2014; 69(4):420-437.
12. Atanaskovic-Markovic M, Caubet JC. Management of drug
hypersensitivity in pediatric population. Expert Rev Clin Pharmacol
2016;9(10):1341-1349.
13. Saretta F, Mori F, Cardinale F, et al. Pediatric drug
hypersensitivity:which diagnostic tests? Acta Biomed 2019;90 (Supll
3):94-107.
14. Aberer W, Bitcher A, Romano A, et al. Drug provocation testing in
the diagnosis of drug hypersensitivity reactions: general consideration.
Allergy 2003;58:854-863.
15. Mayorga C, Didier EG, Lang D, et al. Controversies in drug allergy:In vitro testing. J Allergy Clin Immunol 2019;143:56-65.
16. Mill C, Primeau MN, Medoff E, et al. Assessing the Diagnostic
Properties of a Graded Oral Provocation Challenge for the Diagnosis of
Immediate and Nonimmediate Reactions to Amoxicillin in Children. JAMA
Pediatr 2016;170(6):e160033.
17. Moral L, Caubet JC. Oral challenge without skin tests in children
with non-severe beta-lactam hypersensitivity: Time to change the
paradigm? Pediatr Allergy Immunol 2017;28:724-727.
18. Confino-Cohen R, Rosman Y, Meir-Shafrir K, et al. Oral Challenge
without Skin Testing Safely Excludes Clinically Significant
Delayed-Onset Penicillin Hypersensitivity. J Allergy Clin Immunol Pract
2017;5:669-675.
19. Vyles D, Adams J, Chiu A, Simpson P, Nimmer M, Brousseau DC. Allergy
Testing in Children With Low-Risk Penicillin Allergy Symptoms.
Pediatrics 2017;140(2):e20170471.
20. Kuruvilla M, Thomas J. Direct oral amoxicillin challenge without
antecedent penicillin skin testing in low-riak patients. Ann Allergy
Asthma Immunol 2018;121(5):627-628.
21. Macy E, Vyles D. Who needs penicillin testing? Ann Allergy Asthma
Immunol 2018;121:523-529.
22. Ibanez MD, del Rio PR, Lasa EM, et al. Prospective assesment of
diagnostic tests for pediatric penicillin allergy,from clinical history
to challenge tests. Ann Allergy Asthma Immunol 2018;121(2):235-244.e3.
23. Iammatteo M, Arango SA, Ferastraoaru D, et al. Safety and Outcommes
of Oral Graded Challenges to Amoxicillin without Prior Skin Testing. J
Allergy Clin Immunol Pract 2019;7:236-243.
24. Vila L, Garcia V, Azcona OM, Pineiro L, Meijide A, Balboa V. Mild to
moderate hypersensitivity reactions to beta-lactams in children: a
single-centre retrospective review. BMJ Paediatrics Open 2019;3:e000435.
25. Macy E, Ensina LF. Is Skin testing Required Prior to Drug
Challenges? J Allergy Clin immunol Pract 2019;7(2):412-417.
26. Celik IK, Guvenir H, Hurmuzlu S, et al. The negative predictive
value of 5-day drug provocation test in nonimmediate beta-lactam allergy
in children. Ann Allergy Asthma Immunol 2020;124:494-499.
27. Manuyakorn W, Singvijarn P, Benjaponpitak S, et al. Skin testing
with β-lactam antibiotics for diagnosis of β-lactam hypersensitivity in
children. Asian Pac J Allergy Immunol 2016;34:242-247.
28. Diaferio L, Chiriac AM, Leoni MC, et al. Skin tests are important in
children with β-lactam hypersensitivity, but may be reduced in number.
Pediatr Allergy Immunol 2019;30(4):462-468.
29. Chiriac AM, Rerkpattanapipt T, Bousquet PJ, Molinari N, Demoly P.
Optimal step doses for drug provocation tests to prove beta-lactam
hypersensitivity. Allergy 2017;72(4):552-561.
30. Rodriguez RG, Lozano LM, Ortega AE, Segade JB, Bonilla PG, Torrijos
EG. Provocation Tests in Nonimmediate Hypersensitivity Reactions to
β-Lactam Antibiotics in Children: Are Extended Challenges Needed? J
Allergy Clin Immunol Pract 2019;7:265-269.
31. Labrosse R, Paradis L, Lacombe-Barrios J, et al. Efficacy and Safety
of 5-Day Challenge for the Evaluation of Nonsevere Amoxicillin Allergy
in Children. J allergy Clin Immunol pract 2018;6(5):1673-1680.
32. Phillips EJ, Bigliardi P, Bircher AJ, et al. Controversies in drug
allergy: Testing for delayed reactions. J Allergy Clin Immunol
2019;143:66-73.